Literature DB >> 11091040

In vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteria.

R Schaumann1, G Ackermann, B Pless, M C Claros, E J Goldstein, A C Rodloff.   

Abstract

The in vitro activities of fourteen antimicrobial agents were tested against 292 clinical isolates of obligately anaerobic bacteria using the broth microdilution technique. Taking all strains as a group the MIC(50/90) (mg/l) values were metronidazole and imipenem 0.25/1, meropenem 0.25/0.5, trovafloxacin 0.25/1, gatifloxacin and moxifloxacin 0.5/2, levofloxacin 2/16, ciprofloxacin 4/32, clindamycin 0.5/8, amoxycillin/clavulanate 1/4, doxycycline and chloramphenicol 2/4, erythromycin 4/>32 and penicillin G 16/>32.

Mesh:

Substances:

Year:  2000        PMID: 11091040     DOI: 10.1016/s0924-8579(00)00186-2

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  8 in total

1.  Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study.

Authors:  B Al-Nawas; C Walter; T Morbach; N Seitner; E Siegel; M Maeurer; F Krummenauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-29       Impact factor: 3.267

2.  In vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.

Authors:  Reiner Schaumann; Matthias Funke; Eva Janssen; Arne C Rodloff
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

3.  Bacterial colonization of microbial biofilms in oral squamous cell carcinoma.

Authors:  J Bolz; E Dosá; J Schubert; A W Eckert
Journal:  Clin Oral Investig       Date:  2013-06-22       Impact factor: 3.573

4.  Bacteroides fragilis group: trends in resistance.

Authors:  Manfred Fille; Monica Mango; Matthias Lechner; Reiner Schaumann
Journal:  Curr Microbiol       Date:  2006-01-31       Impact factor: 2.188

5.  Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses.

Authors:  Ingo Sobottka; Karl Wegscheider; Ludwig Balzer; Rainer H Böger; Olaf Hallier; Ina Giersdorf; Thomas Streichert; Munif Haddad; Ursula Platzer; Georg Cachovan
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

6.  Moxifloxacin in the treatment of skin and skin structure infections.

Authors:  David Rp Guay
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

7.  Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial.

Authors:  Hendrik Harms; Konstantin Prass; Christian Meisel; Juliane Klehmet; Witold Rogge; Christoph Drenckhahn; Jos Göhler; Stefan Bereswill; Ulf Göbel; Klaus Dieter Wernecke; Tilo Wolf; Guy Arnold; Elke Halle; Hans-Dieter Volk; Ulrich Dirnagl; Andreas Meisel
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

8.  Analyses of publicly available Hungatella hathewayi genomes revealed genetic distances indicating they belong to more than one species.

Authors:  Laura E Hernández-Juárez; Margarita Camorlinga; Alfonso Méndez-Tenorio; Judith Flores Calderón; B Carol Huang; Dj Darwin R Bandoy; Bart C Weimer; Javier Torres
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.